Glenn Jaffe, MD
Ophthalmology · Durham, NCNPI 1255415311
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $132,500 of the $218,447 with a category attached, or 60.7%. 21 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 55.2% of the total. Reporting peaked in 2019 at $100,060 and has fallen 97.7% since, to $2,280 in 2025. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $2162.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$121K
- F. Hoffmann-la Roche AG$27K
- Regeneron$17K
- Bausch & Lomb Americas Inc.$16K
- Eyepoint US, Inc.$15K
- Ocular Therapeutix, Inc.$13K
- plus $11K from 15 others
Across 426 payments — averaging $89,976 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$29.2M
- Roche TCRC, Inc.$7.1M
- F. Hoffmann-la Roche AG$1.5M
- Hoffmann-la Roche Limited$221K
- PTC Therapeutics, Inc.$112K
- Regeneron$74K
- plus $88K from 5 others
What the payments were for
- Consulting fees$78,41436%
- Speaking & faculty fees$132,50061%
- Travel & lodging$1,6411%
- Food & beverage$5,6293%
- Gifts$2630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $120,616 |
| F. Hoffmann-la Roche AG | 14 | $27,118 |
| Regeneron | 8 | $16,512 |
| Bausch & Lomb Americas Inc. | 10 | $15,636 |
| Eyepoint US, Inc. | 18 | $14,597 |
| Ocular Therapeutix, Inc. | 12 | $13,006 |
| Genentech, Inc. | 10 | $8,442 |
| Hexal AG | 1 | $475 |
| Alimera Sciences, Inc. | 4 | $403 |
| Regeneron Healthcare Solutions, Inc. | 2 | $245 |
| Apellis Pharmaceuticals, Inc. | 2 | $225 |
| Heidelberg Engineering, Inc. | 1 | $205 |
| Coherus Oncology, Inc. | 2 | $168 |
| Dutch Ophthalmic, USA | 1 | $150 |
| Alcon Research LLC | 1 | $148 |
| Carl Zeiss Meditec, Inc. | 1 | $142 |
| ANI Pharmaceuticals, Inc. | 1 | $122 |
| AbbVie | 1 | $103 |
| Topcon Healthcare, Inc. | 2 | $86 |
| Biocryst Pharmaceuticals, Inc. | 1 | $25 |
| Novartis | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS$84,000
- VISUDYNE$20,231
- MACUGEN$20,000
- EYLEA$16,499
- RETISERT$15,121
- YUTIQ$8,490
- STELLARIS ELITE$7,500
- EYP-1901$5,917
- XIPERE$1,731
- Lucentis$1,570
- DEXTENZA$443
- Iluvien$375
- Spectralis$205
- EVA, combined machine$150
- TISSUEBLUE$150
- AIR OPTIX$148
- ARTEVO 800$142
- Cimerli$141
- VABYSMO$136
- Syfovre$133
How this compares
$218,447 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 238 | $12,647 |
| Ketorolac Tromethamine | 220 | $7,572 |
| Bromfenac Sodium | 16 | $5,217 |
| Brimonidine Tartrate | 80 | $2,751 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 135 | $2,175 |
| Timolol Maleate | 71 | $1,298 |
| Atropine Sulfate | 16 | $534 |
| Prednisone | 44 | $424 |
| Latanoprost | 31 | $318 |
| Dorzolamide Hcl | 23 | $296 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Durham
- Julie WoodwardDurham$1M
- Lejla VajzovicDurham$681K
- Terry KimDurham$605K
- Leon HerndonDurham$230K
- Robin VannDurham$213K
- Anthony KuoDurham$186K
- Michael RichardDurham$113K
- Priyatham MettuDurham$111K
- Jason LissDurham$69K
- Majda HadziahmetovicDurham$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.